Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack

Zeling Cai,De Cai,Ruiwen Wang,Heng Wang,Ze Yu,Fei Gao,Yuansheng Liu,Yingbo Kang,Zhuomin Wu

DOI: https://doi.org/10.1038/s41598-021-86824-9

IF: 4.6

2021-04-01

Scientific Reports

Abstract:Abstract Dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin within 48 h of acute minor strokes and transient ischemic attacks (TIAs) has been indicated to effectively reduce the rate of recurrent strokes. However, the efficacy of clopidogrel has been shown to be affected by cytochrome P450 2C19 (CYP2C19) polymorphisms. Patients carrying loss-of-function alleles (LoFAs) at a low risk of recurrence (ESRS < 3) cannot benefit from clopidogrel plus aspirin at all and may have an increased bleeding risk. In order to optimize antiplatelet therapy for these patients and avoid the waste of medical resources, it is important to identify the subgroups that genuinely benefit from DAPT with clopidogrel plus aspirin through CYP2C19 genotyping. This study sought to assess the cost-effectiveness of CYP2C19 genotyping to guide drug therapy for acute minor strokes or high-risk TIAs in China. A decision tree and Markov model were constructed to evaluate the cost-effectiveness of CYP2C19 genotyping. We used a healthcare payer perspective, and the primary outcomes included quality-adjusted life years (QALYs), costs and the incremental cost-effectiveness ratio (ICER). Sensitivity analyses were performed to evaluate the robustness of the results. CYP2C19 genotyping resulted in a lifetime gain of 0.031 QALYs at an additional cost of CNY 420.13 (US$ 59.85), yielding an ICER of CNY 13,552.74 (US$ 1930.59) per QALY gained. Probabilistic sensitivity analysis showed that genetic testing was more cost-effective in 95.7% of the simulations at the willingness-to-pay threshold of CNY 72,100 (GDP per capita, US$ 10,300) per QALY. Therefore, CYP2C19 genotyping to guide antiplatelet therapy for acute minor strokes and high-risk TIAs is highly cost-effective in China.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the cost - effectiveness of CYP2C19 genotype testing in China to guide anti - platelet therapy for patients with acute minor stroke or high - risk transient ischemic attack (TIA). Specifically, the researchers constructed a decision - tree and Markov model to evaluate the cost - effectiveness of CYP2C19 genotype testing. The main outcome measures include quality - adjusted life years (QALYs), cost, and incremental cost - effectiveness ratio (ICER). The study aims to determine whether this genotype testing can effectively optimize anti - platelet treatment regimens, reduce the waste of medical resources, and improve patient safety and treatment outcomes.

The research background indicates that dual - anti - platelet therapy (DAPT) using clopidogrel plus aspirin can effectively reduce the recurrence rate within 48 hours after the occurrence of acute minor stroke or TIA. However, the effect of clopidogrel is affected by cytochrome P450 2C19 (CYP2C19) polymorphisms. Patients carrying loss - of - function alleles (LoFAs) cannot benefit from clopidogrel plus aspirin treatment and may increase the risk of bleeding. Therefore, it is particularly important to identify the subgroup of patients who can truly benefit from DAPT through CYP2C19 genotype testing.

The research results show that in China, CYP2C19 genotype testing to guide anti - platelet therapy for patients with acute minor stroke or high - risk TIA is very cost - effective. Each patient can obtain 0.031 QALYs through genotype testing, with an additional cost of 420.13 yuan (about 60 US dollars), and the ICER is an additional payment of 13,552.74 yuan (about 1,930.59 US dollars) for each QALY obtained. Probability - sensitivity analysis shows that in 95.7% of the simulations, gene testing is more cost - effective when willing to pay 72,100 yuan (per capita GDP, about 10,300 US dollars) for each QALY obtained. Therefore, this study believes that in China, CYP2C19 genotype testing to guide anti - platelet therapy for patients with acute minor stroke or high - risk TIA is very worthwhile.